Can I read The Efficacy and Safety of Immunotherapy in Thymic Epithelial Tumors: More Effective, More Risky: a Systematic Review on EtoBox?

The Efficacy and Safety of Immunotherapy in Thymic Epithelial Tumors: More Effective, More Risky: a Systematic Review by Xinyu Song; Jiang Fan; Liang Zhu; Zhehai Wang; Yayi He; Caicun Zhou is a Medicine article available to read on EtoBox.

What is The Efficacy and Safety of Immunotherapy in Thymic Epithelial Tumors: More Effective, More Risky: a Systematic Review about?

## Background Thymic epithelial tumors (TETs) are rare malignant neoplasms originating from thymic epithelial cells. The current treatment for localized TETs is surgical removal. However, 20–30% of thymomas and 70–80% of thymic carcinomas are unresectable, recurrent, or metastatic at the time of detection. The standard therapy for these patients is chemotherapy, but the effect is limited. With a deeper understanding of tumor immunity, immunotherapy for various cancers has rapidly developed. Antibodies against cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have been approved for the treatment of many solid tumors. Compared with traditional treatments, these immune checkpoint inhibitors (ICIs) have better efficacy and lower toxicity. Recently, ICIs have been used more enthusiastically in the treatment of TETs. However, due to the unique biological characteristics of the thymus, immunotherapy usually causes severe immune-related adverse events (irAEs). Most previous studies on immunotherapy in TETs had small sample sizes and reported diverse conclusions. ## Methods We collected relevant studies in PubMed during the last five years and analyzed the

Who reads The Efficacy and Safety of Immunotherapy in Thymic Epithelial Tumors: More Effective, More Risky: a Systematic Review?

Author

Xinyu Song; Jiang Fan; Liang Zhu; Zhehai Wang; Yayi He; Caicun Zhou

Publisher

AME Publishing Company

Published

2021

Language

EN

Field

Medicine (Health Sciences)